Anand et al,1 in their fine article in the February 1993 issue of the Archives, describe the efficacy of an intravitreal sustained-release device containing ganciclovir to control CMV retinitis in patients with acquired AIDS. However, these authors did not report on the survival time of their 22 patients after the diagnosis of CMV retinitis.
According to the data provided by Anand et al1(p225) in Figure 1, we calculated median survival time using the Kaplan-Meier method for the 22 reported patients. Median survival time after diagnosis of CMV retinitis was 5.6 months (Figure).
In contrast, as shown by several studies, median survival time in patients treated with either intravenously administered ganciclovir or foscarnet varies between 8 and more than 12 months.2,3 Therefore, survival time in patients treated with the intravitreal sustained-release device appears to be shorter compared with patients treated with intravenously applied ganciclovir or foscarnet. In our
Geier SA, Sadri I, Bogner JR, Goebel FD. Ganciclovir Intraocular Device and Patient Survival. Arch Ophthalmol. 1994;112(1):20. doi:10.1001/archopht.1994.01090130029005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: